 |
Amylin, Lilly end diabetes partnershipAmylin Pharmaceuticals will pay Eli Lilly and Company $250 million up front and as much as $1.2 billion in the future for rights to their diabetes products, ending what was once one of the drug industry's most successful partnerships. The More… |
Tuesday 24 December 2024
